The UK has approved Eli Lilly’s new Alzheimer’s treatment, donanemab, which has shown promise in slowing cognitive decline. However, the National Institute for Health and Care Excellence (NICE) determined it is too costly for widespread use within the NHS. This decision comes despite the Medicines and Healthcare products Regulatory Agency (MHRA) deeming the drug safe […]
Eli Lilly and Company (NYSE: LLY) announced results from its QWINT-5 phase 3 trial, demonstrating that its once-weekly insulin efsitora alfa offers a comparable reduction in A1C levels to daily insulin degludec for adults with type 1 diabetes. This data, published in The Lancet and presented at the European Association for the Study of Diabetes […]
Eli Lilly and Company has finalised its acquisition of Morphic Holding, Inc. in a landmark $3.2 billion deal, aimed at enhancing treatment options for inflammatory bowel disease (IBD). This acquisition underscores Lilly’s strategic expansion into the gastroenterology sector. The transaction, valued at $57 per share, is a significant premium over Morphic’s recent stock prices, reflecting […]
In a major strategic move, Eli Lilly and Company (NYSE: LLY) has announced a definitive agreement to acquire Morphic Holding, Inc. (NASDAQ: MORF), a biopharmaceutical company known for its innovative work in developing oral integrin therapies. The acquisition, valued at $57 per share in cash, totals approximately $3.2 billion. This acquisition represents a significant premium […]
Eli Lilly and Company (NYSE: LLY) has announced promising results from the SURMOUNT-OSA phase 3 clinical trials of tirzepatide, a novel treatment aimed at moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity. Detailed results, published in The New England Journal of Medicine and presented at the American Diabetes Association’s 84th Scientific Sessions, reveal significant […]
Eli Lilly and Company (NYSE: LLY) revealed compelling outcomes from the SYNERGY-NASH study, showcasing significant efficacy of tirzepatide in treating metabolic dysfunction-associated steatohepatitis (MASH) with advanced fibrosis. The phase 2 trial demonstrated that tirzepatide, in varying dosages, successfully met the primary endpoint, with a substantial percentage of participants achieving MASH resolution without worsening fibrosis after […]
Eli Lilly and Company (Lilly, NYSE: LLY) has released updated data from its ongoing Phase 1/2 clinical trial for olomorasib, showcasing significant advancements in the treatment of advanced solid tumors with KRAS G12C mutations. The data, which highlights both monotherapy and combination therapy results with Merck’s KEYTRUDA (pembrolizumab), was presented at the prestigious 2024 American […]
In a historic move for the pharmaceutical industry, Eli Lilly and Company (NYSE: LLY) has announced a staggering $5.3 billion expansion of its Lebanon, Indiana manufacturing site. This investment increases the total commitment to this site to $9 billion, aimed at boosting the production of active pharmaceutical ingredients (API) for Zepbound (tirzepatide) injection and Mounjaro […]
Eli Lilly and Company (NYSE: LLY) has released positive topline results from the phase 3 SURMOUNT-OSA clinical trials, demonstrating that tirzepatide injection significantly reduces the apnea-hypopnea index (AHI) compared to placebo. Tirzepatide, already known for chronic weight management under the brand names Zepbound in the U.S. and Mounjaro globally, now shows promise in treating moderate-to-severe […]
In a significant advancement for medical science and hearing loss treatment, Akouos, Inc., a wholly owned subsidiary of Eli Lilly and Company (NYSE: LLY), has unveiled encouraging initial clinical results from its Phase 1/2 AK-OTOF-101 study. This groundbreaking research, which demonstrated pharmacologic hearing restoration within 30 days of AK-OTOF administration in the first participant, marks […]